AIM Vaccine Co (HKSE:06660) Capex-to-Operating-Income : 0.00 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is AIM Vaccine Co Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

AIM Vaccine Co's Capital Expenditure for the six months ended in Dec. 2023 was HK$-208.55 Mil. Its Operating Income for the six months ended in Dec. 2023 was HK$-174.72 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

AIM Vaccine Co Capex-to-Operating-Income Historical Data

The historical data trend for AIM Vaccine Co's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM Vaccine Co Capex-to-Operating-Income Chart

AIM Vaccine Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Capex-to-Operating-Income

2.07

1.38

AIM Vaccine Co Semi-Annual Data
	Dec19	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Capex-to-Operating-Income	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of AIM Vaccine Co's Capex-to-Operating-Income

For the Biotechnology subindustry, AIM Vaccine Co's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AIM Vaccine Co's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM Vaccine Co's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where AIM Vaccine Co's Capex-to-Operating-Income falls into.

AIM Vaccine Co Capex-to-Operating-Income Calculation

AIM Vaccine Co's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-329.933)	/	-492.966
	=	N/A

AIM Vaccine Co's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-208.549)	/	-174.721
	=	N/A

AIM Vaccine Co (HKSE:06660) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

AIM Vaccine Co Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of AIM Vaccine Co's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

AIM Vaccine Co (HKSE:06660) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM Vaccine Co Ltd (HKSE:06660) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

91 Jianguo Road, 25th Floor, Building A, Chaoyang, Beijing, CHN

Website

https://www.aimbio.com

AIM Vaccine Co Ltd is a top full-chain vaccine corporation in China with businesses covering the whole industrial chain ranging from research and development, manufacturing and commercialization. The products available for sale mainly include Recombinant HBV vaccine, Human rabies vaccine, HFRS Vaccine, hepatitis A vaccine (human diploid cell), Group A, C, Y and W135 MPSV, mumps vaccine, freeze-dried human rabies vaccine (Vero cell) and ACYW135 meningococcal polysaccharide vaccine. Geographically, the company generates all of its revenues in the PRC.

Executives

Zhao Yin Jin Rong Kong Gu Shen Zhen You Xian Gong Si	2201 Interest of corporation controlled by you
Zhao Shang Yin Xing Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong You Xian Gong Si	2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si	2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Zi Ben Guan Li Shen Zhen You Xian Gong Si	2201 Interest of corporation controlled by you
Ning Bo Shi Bei Lun Qu Guo You Zi Ben Yun Ying You Xian Gong Si	2201 Interest of corporation controlled by you
Ning Bo Bao Shui Qu Kong Gu You Xian Gong Si	2101 Beneficial owner
Yong Zhou Qing Teng Mao Yi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Li Lihua	2201 Interest of corporation controlled by you
Shang Hai Xun Jing Qi Ye Guan Li Zhong Xin You Xian He Huo	2201 Interest of corporation controlled by you
Zhu Hai Tong Dao Ming Tian Tou Zi He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Mei Hua Sheng Wu Ke Ji Ji Tuan Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
La Sa Mei Hua Sheng Wu Tou Zi Kong Gu You Xian Gong Si	2101 Beneficial owner
Xi Zang Dong Fang Zhi Hui Tou Zi Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Shen Yang Qian Qian Qi Ye Guan Li Zi Xun You Xian Gong Si	2101 Beneficial owner

AIM Vaccine Co (HKSE:06660) Headlines

No Headlines